Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imprime PGG plus Pembrolizumab in Stage III Melanoma
NCT04995094Phase 2Withdrawn
- Sponsor
- HiberCell
- Start
- Aug 2021
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of odetiglucan in melanoma, sponsored by HiberCell. Planned start Aug 2021; status: withdrawn.
02
Drugs
odetiglucan
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04995094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995094.